Developing Mouse Models of Breast Cancer Using Tissue Samples From Women With Breast Cancer
RATIONALE: Changing the genes in laboratory mice to create a living model of human breast cancer may help doctors learn more about breast cancer.
PURPOSE: This research study is developing mouse models of breast cancer using tissue samples that were previously collected from women with breast cancer.
|Breast Cancer||Other: laboratory biomarker analysis Other: medical chart review|
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Developing In-Vivo Models of Human Breast Cancer|
- Development of new in vivo models of human breast cancer [ Time Frame: 1 year ]
- Correlation of response in this model to actual treatment outcome in patients, if the in vivo model proven feasible [ Time Frame: 5 years ]
|Study Start Date:||February 2007|
|Estimated Study Completion Date:||March 2018|
|Primary Completion Date:||May 15, 2017 (Final data collection date for primary outcome measure)|
|breast cancer patients||
Other: laboratory biomarker analysis
Tissue samples will either be collected at the time of medically indicated surgical procedures or through research core biopsies. A sample of urine will also be obtained. Blood will be collected via venipuncture and lymphocytes (mononuclear cells) separated and processed as a source of normal DNA and normal cells.Other: medical chart review
patient chart review will occur in conjunction with patient data collection for final analyses.
- To develop new in vivo models of human breast cancer.
- To correlate response in this model to actual treatment outcome in patients, if the in vivo model is proven feasible.
OUTLINE: Previously collected breast tumor fragments are implanted into the renal capsule site of SCID mouse hosts (mouse with severe combined immune deficiency) to establish metastatic spread patterns, and both histologic and molecular tumor characteristics.
Patients' medical charts are reviewed to obtain relevant information, including general demographics, smoking and alcohol use, as well as outcome data such as survival and response to treatment.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00897468
|United States, Tennessee|
|Vanderbilt-Ingram Cancer Center|
|Nashville, Tennessee, United States, 37232-6838|
|Principal Investigator:||A. Bapsi Chakravarthy, MD||Vanderbilt-Ingram Cancer Center|